Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer
Jul 1, 2009, 00:00 AM
10.1111/j.1524-4733.2009.00564.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60724-3/fulltext
Section Title :
Section Order :
25
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60724-3&doi=10.1111/j.1524-4733.2009.00564.x
HEOR Topics :
- Cost/Cost of Illness/Resource Use Studies
- Cost-comparison, Effectiveness, Utility, Benefit Analysis
- Economic Evaluation
- Oncology
- Specific Diseases & Conditions